Tumor-infiltrating CD11b+ B cells displayed higher levels of MHC-II compared to their CD11b− counterparts in the αCD40-treated groups (Fig. 6h), indicating an increased capability to interact with CD4+ T cells. This evidence concerns the gene ITGAM and neoplasm.